Omalizumab: now licensed as adjunct for urticaria

Omalizumab (Xolair), which was originally licensed for IgE-mediated asthma, is now indicated as adjunctive therapy for chronic spontaneous urticaria. In our New products review, Steve Chaplin presents the data relating to its efficacy and adverse events, and Dr Clive Grattan discusses its place in therapy.

Omalizumab now licensed as adjunct for urticaria

Add yours ↓
Web design and marketing agency Leamington Spa